Nivolumab serum concentration in metastatic melanoma patients could be related to outcome and enhanced immune activity: a gene profiling retrospective analysis

BACKGROUND: Nivolumab is an anti-PD-1 antibody approved for treating metastatic melanoma (MM), for which still limited evidence is available on the correlation between drug exposure and patient outcomes. METHODS: In this observational retrospective study, we assessed whether nivolumab concentration...

Descripción completa

Detalles Bibliográficos
Autores principales: Mallardo, Domenico, Giannarelli, Diana, Vitale, Maria Grazia, Galati, Domenico, Trillò, Giusy, Esposito, Assunta, Isgrò, Maria Antonietta, D'Angelo, Grazia, Festino, Lucia, Vanella, Vito, Trojaniello, Claudia, White, Andrew, De Cristofaro, Teresa, Bailey, Michael, Pignata, Sandro, Caracò, Corrado, Petrillo, Antonella, Muto, Paolo, Maiolino, Piera, Budillon, Alfredo, Warren, Sarah, Cavalcanti, Ernesta, Ascierto, Paolo Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9693654/
https://www.ncbi.nlm.nih.gov/pubmed/36424033
http://dx.doi.org/10.1136/jitc-2022-005132

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9693654/
https://www.ncbi.nlm.nih.gov/pubmed/36424033
http://dx.doi.org/10.1136/jitc-2022-005132

Ejemplares similares